Reduced axonal motor protein expression in non-Lesional grey matter in multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 7, 2014, Pages 812-821

  Hares, K ^a   Kemp, K ^a   Rice, C ^a   Gray, E ^a   Scolding, N ^a   Wilkins, A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Aaxonal transport; Axonal injury; Grey matter; KIF1B; KIF21B; KIF5A; Kinesin; Multiple sclerosis; Protein expression

Indexed keywords

GALACTOSYLCERAMIDASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KIF1B PROTEIN; KIF21B PROTEIN; KIF5A PROTEIN; KINESIN; MOLECULAR MOTOR; NEURON SPECIFIC ENOLASE; PEROXIDASE; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN; KIF1B PROTEIN, HUMAN; KIF2B PROTEIN, HUMAN; KIF5A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENOTYPE; GRAY MATTER; HUMAN; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; OLIGODENDROGLIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; CENTRAL NERVOUS SYSTEM; DEMYELINATION; IMMUNOBLOTTING; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CASE CONTROL STUDY; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DOWN REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GRAY MATTER; HUMANS; KINESIN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RNA, MESSENGER;

EID: 84902176651     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513508836     Document Type: Article

References (30)

1. Wilkins A and Scolding N. Protecting axons in multiple sclerosis. Mult Scler 2008; 14: 1013-1025.
2. Kreutzer M, Seehusen F, Kreutzer R, et al. Axonopathy is associated with complex axonal transport defects in a model of multiple sclerosis. Brain Pathol 2012; 22: 454-471.
3. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
4. Millecamps S and Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013; 14: 161-176.
5. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399. (Pubitemid 27153632)
6. Gray E, Rice C, Nightingale H, et al. Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Mult Scler 2013; 19: 153-161.
7. Hirokawa N, Noda Y, Tanaka Y, et al. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 2009; 10: 682-696.
8. Xia CH, Roberts EA, Her LS, et al. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol 2003; 161: 55-66. (Pubitemid 36459079)
9. Alcina A, Fedetz M, Fernandez O, et al. Identification of a functional variant in the KIF5A-CYP27B1-METTL1- FAM119B locus associated with multiple sclerosis. J Med Genet 2013; 50: 25-33.
10. Lyons DA, Naylor SG, Scholze A, et al. Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons. Nat Genet 2009; 41: 854-858.
11. Goris A, Boonen S, D'Hooghe MB, et al. Replication of KIF21B as a susceptibility locus for multiple sclerosis. J Med Genet 2010; 47: 775-776.
12. Gray E, Ginty M, Kemp K, et al. The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflam 2012; 9: 63.
13. Dey R, Kemp K, Gray E, et al. Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with Friedreich's ataxia. Cerebellum 2012; 11: 861-871.
14. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
15. Schirmer L, Albert M, Buss A, et al. Substantial early, but nonprogressive neuronal loss in multiple sclerosis (MS) spinal cord. Ann Neurol 2009; 66: 698-704.
16. Aizawa H, Sekine Y, Takemura R, et al. Kinesin family in murine central nervous system. J Cell Biol 1992; 119: 1287- 1296.
17. Kamal A, Stokin GB, Yang Z, et al. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 2000; 28: 449-459.
18. Kanai Y, Okada Y, Tanaka Y, et al. KIF5C, a novel neuronal kinesin enriched in motor neurons. J Neurosci 2000; 20: 6374-6384.
19. Friede RL and Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. The Anatomical Record 1970; 167: 379-387.
20. Marszalek JR, Weiner JA, Farlow SJ, et al. Novel dendritic kinesin sorting identified by different process targeting of two related kinesins: KIF21A and KIF21B. J Cell Biol 1999; 145: 469-479. (Pubitemid 29215712)
21. Mitchell CS and Lee RH. Cargo distributions differentiate pathological axonal transport impairments. J Theoretical Biol 2012; 300: 277-291.
22. Nangaku M, Sato-Yoshitake R, Okada Y, et al. KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. Cell 1994; 79: 1209-1220.
23. Meinl E and Hohlfeld R. Immunopathogenesis of multiple sclerosis: MBP and beyond. Clin Exp Immunol 2002; 128: 395-397. (Pubitemid 34639297)
24. Kenealy SJ, Pericak-Vance MA and Haines JL. The genetic epidemiology of multiple sclerosis. J Neuroimmunol 2003; 143: 7-12. (Pubitemid 37336469)
25. Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002; 71: 1189-1194. (Pubitemid 35305237)
26. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurol 2003; 184: S106-110. (Pubitemid 37338709)
27. DeLuca GC, Ramagopalan SV, Cader MZ, et al. The role of hereditary spastic paraplegia related genes in multiple sclerosis. A study of disease susceptibility and clinical outcome. J Neurol 2007; 254: 1221-1226. (Pubitemid 350112351)
28. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862. (Pubitemid 47347319)
29. Hafler JP, Maier LM, Cooper JD, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immunity 2009; 10: 5-10.
30. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.